T1-Weighted Dynamic Contrast-Enhanced MR Perfusion Imaging Characterizes Tumor Response to Radiation Therapy in Chordoma

References

1. 1.↵
   2. Walcott BP,
   3. Nahed BV,
   4. Mohyeldin A, et al

   . Chordoma: current concepts, management, and future directions. Lancet Oncol 2012;13:e69–76 doi:10.1016/S1470-2045(11)70337-0 pmid:22300861

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Healey JH,
   3. Lane JM

   . Chordoma: a critical review of diagnosis and treatment. Orthop Clin North Am 1989;20:417–26 pmid:2662114

   PubMedWeb of Science
3. 3.↵
   2. Stiller CA,
   3. Trama A,
   4. Serraino D, et al

   ; RARECARE Working Group. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer 2013;49:684–95 doi:10.1016/j.ejca.2012.09.011 pmid:23079473

   CrossRefPubMedWeb of Science
4. 4.↵
   2. McMaster ML,
   3. Goldstein AM,
   4. Bromley CM, et al

   . Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control 2001;12:1–11 doi:10.1023/A:1008947301735 pmid:11227920

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Sung MS,
   3. Lee GK,
   4. Kang HS, et al

   . Sacrococcygeal chordoma: MR imaging in 30 patients. Skeletal Radiol 2005;34:87–94 doi:10.1007/s00256-004-0840-4 pmid:15480648

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Smolders D,
   3. Wang X,
   4. Drevelengas A, et al

   . Value of MRI in the diagnosis of non-clival, non-sacral chordoma. Skeletal Radiol 2003;32:343–50 doi:10.1007/s00256-003-0633-1 pmid:12719927

   CrossRefPubMed
7. 7.↵
   2. Rodallec MH,
   3. Feydy A,
   4. Larousserie F, et al

   . Diagnostic imaging of solitary tumors of the spine: what to do and say. Radiographics 2008;28:1019–41 doi:10.1148/rg.284075156 pmid:18635627

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Llauger J,
   3. Palmer J,
   4. Amores S, et al

   . Primary tumors of the sacrum: diagnostic imaging. AJR Am J Roentgenol 2000;174:417–24 doi:10.2214/ajr.174.2.1740417 pmid:10658718

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Chugh R,
   3. Tawbi H,
   4. Lucas DR, et al

   . Chordoma: the nonsarcoma primary bone tumor. Oncologist 2007;12:1344–50 doi:10.1634/theoncologist.12-11-1344 pmid:18055855

   Abstract/FREE Full Text
10. 10.↵
    2. Stacchiotti S,
    3. Sommer J

    . Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol 2015;16:e71–83 doi:10.1016/S1470-2045(14)71190-8 pmid:25638683

    CrossRefPubMed
11. 11.↵
    2. Fuchs B,
    3. Dickey ID,
    4. Yaszemski MJ, et al

    . Operative management of sacral chordoma. J Bone Joint Surg Am 2005;87:2211–16 pmid:16203885

    Abstract/FREE Full Text
12. 12.↵
    1. Jackson A,
    2. Buckley D,
    3. Parker G

    2. Parker G,
    3. Buckley D

    . Tracer kinetic modeling for T1-weighted DCE-MRI. In: Jackson A, Buckley D, Parker G. Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Oncology. Berlin: Springer; 2005:81–91
13. 13.↵
    2. Chu S,
    3. Karimi S,
    4. Peck KK, et al

    . Measurement of blood perfusion in spinal metastases with dynamic contrast-enhanced magnetic resonance imaging: evaluation of tumor response to radiation therapy. Spine 2013;38:E1418–24 doi:10.1097/BRS.0b013e3182a40838 pmid:23873238

    CrossRefPubMed
14. 14.↵
    2. Saha A,
    3. Peck KK,
    4. Lis E, et al

    . Magnetic resonance perfusion characteristics of hypervascular renal and hypovascular prostate spinal metastases: clinical utilities and implications. Spine 2014;39:E1433–40 doi:10.1097/BRS.0000000000000570 pmid:25188594

    CrossRefPubMed
15. 15.↵
    2. Lang N,
    3. Su MY,
    4. Xing X, et al

    . Morphological and dynamic contrast enhanced MR imaging features for the differentiation of chordoma and giant cell tumors in the axial skeleton. J Magn Reson Imaging 2017;45:1068–75 doi:10.1002/jmri.25414 pmid:27490009

    CrossRefPubMed
16. 16.↵
    2. Tofts PS,
    3. Brix G,
    4. Buckley DL, et al

    . Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32 pmid:10508281

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Chen KW,
    3. Yang HL,
    4. Lu J, et al

    . Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. J Neurooncol 2011;101:357–63 doi:10.1007/s11060-010-0263-0 pmid:20549300

    CrossRefPubMed
18. 18.↵
    2. Kawashima A,
    3. Okada Y,
    4. Nakanishi I, et al

    . Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. Gen Diagn Pathol 1997;142:129–37 pmid:9065576

    PubMed
19. 19.↵
    2. Kumta SM,
    3. Huang L,
    4. Cheng YY, et al

    . Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci 2003;73:1427–36 doi:10.1016/S0024-3205(03)00434-X pmid:12850503

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Kaya M,
    3. Wada T,
    4. Kawaguchi S, et al

    . Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 2002;86:864–69 doi:10.1038/sj.bjc.6600201 pmid:11953816

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Johnson LM,
    3. Turkbey B,
    4. Figg WD, et al

    . Multiparametric MRI in prostate cancer management. Nature Rev Clin Oncol 2014;11:346–53 doi:10.1038/nrclinonc.2014.69

    CrossRefPubMed
22. 22.↵
    2. Park HJ,
    3. Griffin RJ,
    4. Hui S, et al

    . Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 2012;177:311–27 doi:10.1667/RR2773.1 pmid:22229487

    CrossRefPubMed
23. 23.↵
    2. De Coninck T,
    3. Jans L,
    4. Sys G, et al

    . Dynamic contrast-enhanced MR imaging for differentiation between enchondroma and chondrosarcoma. Eur Radiol 2013;23:3140–52 doi:10.1007/s00330-013-2913-z pmid:23771600

    CrossRefPubMed
24. 24.↵
    2. Røe K,
    3. Kakar M,
    4. Seierstad T, et al

    . Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study. Radiat Oncol 2011;6:65 doi:10.1186/1748-717X-6-65 pmid:21651782

    CrossRefPubMed
25. 25.↵
    2. Cao Y

    . The promise of dynamic contrast-enhanced imaging in radiation therapy. Semin Radiat Oncol 2011;21:147–56 doi:10.1016/j.semradonc.2010.11.001 pmid:21356482

    CrossRefPubMed
26. 26.↵
    2. Grabham P,
    3. Sharma P

    . The effects of radiation on angiogenesis. Vasc Cell 2013;5:1 doi:10.1186/2045-824X-5-19 pmid:24160185

    CrossRefPubMed
27. 27.↵
    2. Thomas AA,
    3. Arevalo-Perez J,
    4. Kaley T, et al

    . Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. J Neurooncol 2015;125:183–90 doi:10.1007/s11060-015-1893-z pmid:26275367

    CrossRefPubMed